Dyne Reports Wider Loss in Fiscal Q2
Dyne Therapeutics (NASDAQ:DYN), a biopharmaceutical company focused on advancing therapies for serious muscle diseases, released its results for the second quarter of fiscal 2025 on July 28, 2025. In the release, Dyne reported a net loss per share of $(0.97) (GAAP), missing analyst estimates of $(0.94) GAAP. The period featured no revenue, as expected at this pre-commercial stage. The quarter saw a significant jump in operating expenses, especially research and development, as the company advanced its two lead candidates into late-stage trials. Dyne also secured new financing through a $230 million public stock offering in July and a $275 million loan facility, giving it a cash runway through the third quarter of 2027. Overall, the period was marked by clinical progress, higher costs, and strengthened cash reserves.
Source: Analyst estimates for the quarter provided by FactSet.
Dyne Therapeutics is developing specialized medicines for serious genetic muscle disorders. Its lead programs target myotonic dystrophy type 1 with DYNE-101 and Duchenne muscular dystrophy with DYNE-251. Both drugs are currently in mid- to late-stage clinical development.
Source Fool.com
